Showing results (571-580 of 6,664) with videos related to

Sort By:
Pageof 667
Annals of Hematology|December 25, 2016
Carotenoid intake and risk of non-Hodgkin lymphoma: a systematic review and dose-response meta-analysis of observational studiesFeifei Chen, Jiyi Hu, Ping Liu, et al.
Annals of Hematology|December 15, 2016
GM-CSF treatment is not effective in congenital neutropenia patients due to its inability to activate NAMPT signalingCorinna Koch, Bardia Samareh, Tatsuya Morishima, et al.
Annals of Hematology|December 15, 2007
Assessment of the psychological effects of genetic screening for hereditary hemochromatosisPeter Elsass, Palle Pedersen, Kristian Husum, et al.
Annals of Hematology|January 26, 2008
The sepsis-related Organ Failure Assessment (SOFA) score is predictive for survival of patients admitted to the intensive care unit following allogeneic blood stem cell transplantationFrank Neumann, Oliver Lobitz, Roland Fenk, et al.
Annals of Hematology|April 1, 1991
Ratio of complement receptor over Fc-receptor III expression: a sensitive parameter to monitor granulocyte-macrophage colony-stimulating factor effects on neutrophilsD Maurer, G F Fischer, T Felzmann, et al.
Annals of Hematology|February 16, 2008
Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literatureM de Fost, T A Out, F A de Wilde, et al.
Annals of Hematology|March 1, 2014
Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101Ana Carolina dos Santos Ferreira, Marcela Cristina Robaina, Lídia Maria Magalhães de Rezende, et al.
Annals of Hematology|February 1, 2017
Low-dose pembrolizumab for relapsed/refractory Hodgkin lymphoma: high efficacy with minimal toxicityThomas S Y Chan, Tsan-Hei Luk, June S M Lau, et al.
Annals of Hematology|January 20, 2017
Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trialLaura Magnano, Silvia Montoto, Eva González-Barca, et al.
Annals of Hematology|January 25, 2017
The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registryAntoinetta J M Beijers, Simone Oerlemans, Floortje Mols, et al.
Pageof 667